ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1899

Life Expectancy a Swiss Cohort of Patients with Ankylosing Spondylitis: A 35-Year Follow-up Study
Abstract Number: 1198

Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Patients with Rheumatoid Arthritis
Abstract Number: 0037

Lipoprotein-associated Phospholipase A2: A New Biomarker for Lymphoma Development in Sjögren’s Syndrome
Abstract Number: 0700

Lipoxin A4 Induces Lipid Class Switching and Inflammation Resolution at the Genomic Level in Human Osteoarthritis
Abstract Number: 0703

Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect
Abstract Number: 0254

LLDAS (Low Lupus Disease Activity State) and Remission Prevent Damage Accrual in Systemic Lupus Erythematosus (SLE) Patients in a Primarily Mestizo Cohort
Abstract Number: 1485

LNA043, a Novel Cartilage Regenerative Treatment for Osteoarthritis: Results from a First-In-Human Trial in Patients with Knee Osteoarthritis
Abstract Number: 0705

lncRNA H19 and Micro RNA 675-3p Are Altered by Visfatin During Osteogenesis
Abstract Number: 0298

Local Genetic Ancestry Associations with Clinical Features of Systemic Lupus Erythematosus
Abstract Number: 2051

Localized versus Systemic Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Database
Abstract Number: 0749

Locating Cellular Subsets in Rheumatoid Arthritis Synovium Using CO-Detection by IndEXing (CODEX)
Abstract Number: 0052

Loneliness and Social Isolation Are Important Social Determinants Among Patients from Minority Communities with Rheumatic Diseases
Abstract Number: 1914

Long Non-coding RNA HOTAIR Induces GLI2 Expression Through Notch Signalling in Systemic Sclerosis Dermal Fibroblasts
Abstract Number: L08

Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)
Abstract Number: 0720

Long Term Efficacy and Safety of Triamcinolone Hexacetonide versus Triamcinolone Acetonide Intraarticular Injection for Juvenile Idiopathic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].